Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 1, 2020

BioPharm International

  • BioPharm International-05-01-2020
  • Volume 33
  • Issue 5

ReNu Single-Use Technology Cartridge Assemblies

ReNu SU (single-use) Technology cartridge assemblies from Watson-Marlow Fluid Technology Group are designed for the development and production of personalized medicines.

ReNu SU (single-use) Technology cartridge assemblies from Watson-Marlow Fluid Technology Group are designed for the development and production of personalized medicines. Available with CPC AseptiQuik, Pall Kleenpak Presto, or GE Readymate aseptic connectors, the devices can be integrated directly into a customized fluid path, allowing for fast bioprocess integration while eliminating alignment errors.

The cartridge assemblies are equipped to work with the company’s quantum peristaltic pump, which allows for a change in pump technology by providing higher accuracy with flow linearity without back pressure. Additionally, the cartridge assemblies offer lot traceability on every component, ISO Class 7 cleanroom manufactured and packaged assemblies, and product sterility of 10-6 SAL per ANSI/AAMI/ISO 11137 guidelines.

Watson-Marlow Fluid Technology Group



 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.